Trial Profile
An Open Label Pharmacokinetic Study Of Gabapentin In Japanese Subjects With Renal Impairment Including Hemodialysis.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 04 Feb 2021
Price :
$35
*
At a glance
- Drugs Gabapentin (Primary)
- Indications Epilepsy
- Focus Pharmacokinetics
- Sponsors Pfizer; Viatris Inc
- 28 Oct 2008 Actual patient number (8) added as reported by ClinicalTrials.gov.
- 28 Oct 2008 Planned end date changed from 1 Dec 2008 to 1 Dec 2007 as reported by ClinicalTrials.gov.
- 28 Oct 2008 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.